2022
DOI: 10.26502/acbr.50170236
|View full text |Cite
|
Sign up to set email alerts
|

Effectivity Analysis of COVID-19 Vaccines Against Emerging Variants of SARS-CoV-2

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…The rising burden of cutaneous fungal infections has been a persistently neglected public health problem for decades. This phenomenon remained more pronounced during the global surge of COVID-19 cases when physicians and scientists across the globe were focused on identifying ways to treat or cure SARS-CoV-2 infections [6][7][8][9][10][11][12][13]. The current study is the torchbearer for strategic organizations to develop measures to prevent the future spread of cutaneous fungal infections not only the urban areas but also in rural areas across the globe.…”
Section: Discussionmentioning
confidence: 99%
“…The rising burden of cutaneous fungal infections has been a persistently neglected public health problem for decades. This phenomenon remained more pronounced during the global surge of COVID-19 cases when physicians and scientists across the globe were focused on identifying ways to treat or cure SARS-CoV-2 infections [6][7][8][9][10][11][12][13]. The current study is the torchbearer for strategic organizations to develop measures to prevent the future spread of cutaneous fungal infections not only the urban areas but also in rural areas across the globe.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, we have also examined strong positive results (85%) with SARS-CoV-2 spike protein antibodies among Sputnik V first dose vaccinated people (6). The SARS-CoV-2 has been emerged as serious public health concern (7)(8)(9)(10). Usually, the antibodies can protect for a few months, however the level of antibodies needs to be monitored so that booster doses could be taken with time.…”
mentioning
confidence: 99%